Companies appear wary of developing drugs for gram-negative bacteria

02/28/2010 | New York Times (tiered subscription model), The

Treatments for gram-negative bacteria are rarely pursued by drugmakers because of the bacteria's drug resistance, according to The New York Times. The lack of drugs also stems from the reluctance of developers to invest in antibiotics. The few candidates against gram-negative infection have increased in value, and big companies are licensing them from Calixa Therapeutics and other smaller firms.

View Full Article in:

New York Times (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Project Manager RA - 15000003MD
Abbott
Santa Clara, CA
Director, Site Quality Management
CareFusion
Minneapolis, MN